Published in Emerg Infect Dis on November 01, 2011
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses (2013) 1.37
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res (2013) 1.12
Peramivir and laninamivir susceptibility of circulating influenza A and B viruses. Influenza Other Respir Viruses (2014) 0.84
I222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic Avian Influenza A(H5N1) viruses. PLoS One (2013) 0.83
Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium. J Virol (2015) 0.81
Safety and efficacy of peramivir for influenza treatment. Drug Des Devel Ther (2014) 0.79
Influenza testing, diagnosis, and treatment in the emergency department in 2009-2010 and 2010-2011. Acad Emerg Med (2013) 0.78
Epidemiological, Clinical and Virological Characteristics of Influenza B Virus from Patients at the Hospital Tertiary Care Units in Bangkok during 2011-2014. PLoS One (2016) 0.77
Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens. Antimicrob Agents Chemother (2013) 0.76
Antiviral drug profile of human influenza A & B viruses circulating in India: 2004-2011. Indian J Med Res (2014) 0.75
A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses. J Infect Dis (2014) 0.75
Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother (2008) 5.04
Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother (2006) 4.02
Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis (1998) 3.47
Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis (2006) 3.26
Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA (2007) 3.00
A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis (2006) 2.33
Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med (2010) 2.13
Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis (2008) 1.72
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother (2009) 1.64
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother (2010) 1.63
Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis (2010) 1.49
Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs. Virus Res (2004) 1.22
Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob Agents Chemother (2006) 1.14
Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. Pediatr Infect Dis J (2011) 1.10
Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing. Antiviral Res (2009) 1.09
Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med (2009) 42.75
Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med (2009) 16.13
Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med (2009) 9.06
Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA (2010) 5.94
Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA (2009) 5.84
Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis (2007) 5.21
Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother (2008) 5.04
Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother (2006) 2.69
Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PLoS One (2010) 2.59
Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis (2006) 2.43
Real-time PCR assays for detection of bocavirus in human specimens. J Clin Microbiol (2006) 2.29
Influenza is a major contributor to childhood pneumonia in a tropical developing country. Pediatr Infect Dis J (2010) 2.29
Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother (2005) 2.17
Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med (2003) 2.09
Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother (2009) 2.09
Inhalational anthrax outbreak among postal workers, Washington, D.C., 2001. Emerg Infect Dis (2002) 2.03
Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb Mortal Wkly Rep (2015) 2.01
Human coronavirus infections in rural Thailand: a comprehensive study using real-time reverse-transcription polymerase chain reaction assays. J Infect Dis (2007) 1.94
Influenza in outpatient ILI case-patients in national hospital-based surveillance, Bangladesh, 2007-2008. PLoS One (2009) 1.85
Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res (2008) 1.78
Impact of maternal influenza vaccination during pregnancy on the incidence of acute respiratory illness visits among infants. Arch Pediatr Adolesc Med (2006) 1.75
Incidence of influenza-like illness and severe acute respiratory infection during three influenza seasons in Bangladesh, 2008-2010. Bull World Health Organ (2011) 1.74
Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther (2012) 1.68
Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res (2009) 1.66
Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis (2011) 1.66
Household transmission of pandemic (H1N1) 2009, San Antonio, Texas, USA, April-May 2009. Emerg Infect Dis (2010) 1.64
The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis (2005) 1.64
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother (2010) 1.63
Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg Infect Dis (2012) 1.62
Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001. Emerg Infect Dis (2002) 1.59
Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis (2010) 1.49
Epidemiology of 2009 pandemic influenza A (H1N1) deaths in the United States, April-July 2009. Clin Infect Dis (2011) 1.48
Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J Infect Dis (2006) 1.46
Interim estimates of 2013-14 seasonal influenza vaccine effectiveness - United States, February 2014. MMWR Morb Mortal Wkly Rep (2014) 1.44
Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010. J Infect Dis (2011) 1.42
Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment. Antimicrob Agents Chemother (2013) 1.39
Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010. Clin Infect Dis (2012) 1.39
Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerg Infect Dis (2011) 1.38
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother (2010) 1.36
Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005-2009. J Infect Dis (2011) 1.33
Population-based surveillance for 2009 pandemic influenza A (H1N1) virus in Guatemala, 2009. Influenza Other Respir Viruses (2010) 1.30
Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One (2009) 1.30
In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother (2010) 1.29
Multidrug-resistant tuberculosis detection, Latvia. Emerg Infect Dis (2005) 1.28
Incidence of respiratory virus-associated pneumonia in urban poor young children of Dhaka, Bangladesh, 2009-2011. PLoS One (2012) 1.28
A summary of national reports of foodborne outbreaks of Salmonella Heidelberg infections in the United States: clues for disease prevention. J Food Prot (2006) 1.28
Influenza genome analysis using pyrosequencing method: current applications for a moving target. Expert Rev Mol Diagn (2009) 1.26
Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir Ther (2010) 1.26
R292K substitution and drug susceptibility of influenza A(H7N9) viruses. Emerg Infect Dis (2013) 1.25
Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method. Antimicrob Agents Chemother (2009) 1.23
Serologically confirmed household transmission of 2009 pandemic influenza A (H1N1) virus during the first pandemic wave--New York City, April-May 2009. Clin Infect Dis (2011) 1.22
Development of the Respiratory Index of Severity in Children (RISC) score among young children with respiratory infections in South Africa. PLoS One (2012) 1.21
Genomic signature-based identification of influenza A viruses using RT-PCR/electro-spray ionization mass spectrometry (ESI-MS) technology. PLoS One (2010) 1.20
Trachoma decline and widespread use of antimicrobial drugs. Emerg Infect Dis (2004) 1.19
Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses (2010) 1.16
Influenza-associated mortality in 2009 in four sentinel sites in Bangladesh. Bull World Health Organ (2012) 1.15
Prevalence of 2009 pandemic influenza A (H1N1) virus antibodies, Tampa Bay Florida--November-December, 2009. PLoS One (2011) 1.15
Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients--North Carolina, 2009. J Infect Dis (2011) 1.15
Genetically diverse group A streptococci from children in far-western Nepal share high genetic relatedness with isolates from other countries. J Clin Microbiol (2006) 1.14
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. Influenza Other Respir Viruses (2013) 1.13
Prevalence of seropositivity to pandemic influenza A/H1N1 virus in the United States following the 2009 pandemic. PLoS One (2012) 1.13
Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. J Infect Public Health (2009) 1.13
Rates of hospital-acquired respiratory illness in Bangladeshi tertiary care hospitals: results from a low-cost pilot surveillance strategy. Clin Infect Dis (2010) 1.12
A comparison of clinical and epidemiological characteristics of fatal human infections with H5N1 and human influenza viruses in Thailand, 2004-2006. PLoS One (2011) 1.11
Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One (2009) 1.10
Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing. Antiviral Res (2009) 1.09
Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors. J Virol (2005) 1.09
Incidence and etiology of acute lower respiratory tract infections in hospitalized children younger than 5 years in rural Thailand. Pediatr Infect Dis J (2014) 1.09
Intent to receive pandemic influenza A (H1N1) vaccine, compliance with social distancing and sources of information in NC, 2009. PLoS One (2010) 1.08
Understanding influenza virus resistance to antiviral agents; early warning signs for wider community circulation. J Infect Dis (2012) 1.07
Influenza-associated pediatric deaths in the United States, 2004-2012. Pediatrics (2013) 1.07
Estimating the disease burden of pandemic (H1N1) 2009 virus infection in Hunter New England, Northern New South Wales, Australia, 2009. PLoS One (2010) 1.07
A comparison of the epidemiology and clinical presentation of seasonal influenza A and 2009 pandemic influenza A (H1N1) in Guatemala. PLoS One (2010) 1.05
Avian influenza virus A (H5N1), detected through routine surveillance, in child, Bangladesh. Emerg Infect Dis (2009) 1.05
Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. Antiviral Res (2008) 1.03
Monitoring seasonal influenza A evolution: rapid 2009 pandemic H1N1 surveillance with an reverse transcription-polymerase chain reaction/electro-spray ionization mass spectrometry assay. J Clin Virol (2012) 1.02
Reduced influenza antiviral treatment among children and adults hospitalized with laboratory-confirmed influenza infection in the year after the 2009 pandemic. Clin Infect Dis (2012) 1.02
Rapid identification of oseltamivir-resistant influenza A(H1N1) viruses with H274Y mutation by RT-PCR/restriction fragment length polymorphism assay. Antiviral Res (2009) 1.01
Serology as an adjunct to polymerase chain reaction assays for surveillance of acute respiratory virus infections. Clin Infect Dis (2011) 1.01
Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors. Influenza Other Respir Viruses (2013) 1.00